Industry News | 文章中心 | Nanjing Bike Biotechnology Co., Ltd

Milestone new drugs are FDA approved for use in metabolic steatohepatitis

2024-03-22

本文摘自——药融圈
FDA approved the first MLD / heteroection leukodystrophy gene therapy

2024-03-21

本文摘自——药融圈
Future direction of the macrocyclic peptide —— polypeptide drugs

2024-03-20

本文摘自——药精通Bio
Cell Reports: Brain organoids reveal the mechanisms of rare diseases

2024-03-19

本文摘自——药精通Bio
FDA approves the first new drug for metabolic steatohepatitis (NAS H/M ASH)!

2024-03-18

本文摘自——药精通Bio
The first TCR therapy: it sold for 1.8 billion yuan in 2023, up 43%

2024-03-15

本文摘自——药融圈

Pre 31 32 33 34 35 36 37 38 39 Next 39Pages

Contact Us

Add：1st Floor, Building 9, No. 6 Qiande Road, Jiangning District, Nanjing

PE：211100

Wet：www.bicbiotech.com

Email：sales@bicbiotech.com

Sales Department

TEL：86-025-58906079

Copyright © 2023 Nanjing Bic Biotechnology Co., Ltd SU ICP:2024061905-1

Technical:www.nj-gm.com

Consultation with online customer service

Service hotline

025-58906079
18066052887

功能和特性

价格和优惠

获取内部资料